{"result": "(\"entity\"<|>LIRAGLUTIDA<|>ORGANIZATION<|>Liraglutida is an analog of the incretin GLP-1, used for the treatment of type 2 diabetes and obesity, known for its ability to increase insulin release and reduce weight.)\n##\n(\"entity\"<|>FDA<|>ORGANIZATION<|>The FDA is the Food and Drug Administration, which recommended the initiation of a cardiovascular safety study for liraglutida.)\n##\n(\"entity\"<|>ESTUDIO LIGHT<|>EVENT<|>The LIGHT study is a cardiovascular safety study initiated to evaluate the effects of liraglutida.)\n##\n(\"entity\"<|>PACIENTES<|>PERSON<|>Patients participating in the LIGHT study, totaling 8910 individuals.)\n##\n(\"entity\"<|>ORLISTAT<|>ORGANIZATION<|>Orlistat is a reference drug used for weight loss, compared against liraglutida in clinical studies.)\n##\n(\"entity\"<|>ESCALA<|>EVENT<|>The SCALE study series evaluates the efficacy and safety of liraglutida in different obesity situations.)\n##\n(\"entity\"<|>NÚCLEOS HIPOTALÁMICOS<|>GEO<|>Hypothalamic nuclei are brain regions where liraglutida exerts its central effects on appetite regulation.)\n##\n(\"entity\"<|>NEURONAS<|>PERSON<|>Neurons in the hypothalamus that are stimulated by liraglutida to regulate appetite.)\n##\n(\"entity\"<|>NEUROTRANSMISORES<|>PERSON<|>Neurotransmitters that are inhibited by liraglutida in the hypothalamus to reduce appetite.)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>FDA<|>The FDA recommended the initiation of a cardiovascular safety study for liraglutida<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>ESTUDIO LIGHT<|>Liraglutida is being evaluated in the LIGHT study for cardiovascular safety<|>7)\n##\n(\"relationship\"<|>PACIENTES<|>ESTUDIO LIGHT<|>8910 patients are participating in the LIGHT study to assess liraglutida<|>9)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>ORLISTAT<|>Liraglutida is compared against Orlistat in clinical studies for weight loss efficacy<|>6)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>ESCALA<|>Liraglutida is evaluated in the SCALE studies for its effects on obesity<|>7)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>NÚCLEOS HIPOTALÁMICOS<|>Liraglutida acts on the hypothalamic nuclei to regulate appetite<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>NEURONAS<|>Liraglutida stimulates neurons in the hypothalamus to influence appetite<|>8)\n##\n(\"relationship\"<|>LIRAGLUTIDA<|>NEUROTRANSMISORES<|>Liraglutida inhibits neurotransmitters in the hypothalamus to reduce appetite<|>8)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: aglutida es un análogo de la incretina GLP-1 (Gluca-\ncada semana en 1 comp. hasta llegar a 4 comp./día,                     gon Like Peptide-1) que se libera en las células L intesti-\ndistribuidos en 2 tomas. La última dosis se recomienda                 nales tras la ingesta de alimentos. Liraglutida tiene una\nque se tome por la tarde para evitar la aparición de                   homología estructural en un 97% con el GLP-1 nativo,\ninsomnio si se ingiere a la hora de cenar.                             pero le confiere una vida media mucho más prolongada,\n   BN reduce las cifras de presión arterial (–0,9 mm Hg                ya que es resistente a la degradación enzimática de la\nPAS; –1,2 mmHg PAD), pero en menor proporción que                      DPP-IV (dipeptidil peptidasa-IV)22. De esta manera, la ad-\nen placebo (–2,8 y 2,6 mmHg, respectivamente). Tam-                    ministración de liraglutida alcanza concentraciones más\nbién con placebo se disminuye la frecuencia cardiaca                   elevadas y sostenidas de este análogo hormonal. Sus ac-\n(–2,3 lpm) que con esta asociación (–0,2 lpm). Por di-                 ciones son múltiples e interviene en varios órganos don-\ncho motivo, la FDA recomendó que se iniciara un estu-                  de existen receptores de GLP-1; pero básicamente se\ndio    de   seguridad      cardiovascular      (estudio     LIGHT)21.  conoce por su acción de incrementar la liberación de in-\n8910 pacientes han participando en este estudio pros-                  sulina tras la ingestión de comida (de ahí el nombre\npectivo, aleatorizado de no inferioridad de la adminis-                de «incretina») y de frenar la acción hiperglucemiante del\ntración de BN. Un análisis intermedio al 50% de even-                  glucagón, dependiente de glucosa22. Gracias a esta ac-\n---\n                                                                               Tema 8.     Tratamiento farmacológico de la obesidad             137\n\n\n\n%\n   ción dual, liraglutida fue comercializada para el trata-                      1,8-2,4-3 mg/día) frente a placebo y orlistat como\n   miento de la diabetes tipo 2 consiguiendo reducciones                         fármaco de referencia25. Al finalizar el primer año, los\n   de HbA1c en torno al 1,5% en función de las dosis admi-\n   nistradas (1,2 a 1,8 mg/día por vía subcutánea)23.                            pacientes con liraglutida 3 mg perdieron un 9,2% del\n                                                                                 peso inicial (3,1% placebo), lo que supuso que el 73%\n      Pero liraglutida ejerce otras acciones a nivel central,                    de los pacientes perdieran ≥ 5% del peso corporal. Por\n   interviniendo principalmente sobre los núcleos hipota-                        tanto, se eligió la dosis de 3 mg como la más eficaz\n   lámicos, estimulando directamente las neuronas de las                         para la reducción del peso.\n   vías anorexígenas POMC y CART (cocaine and amphe-                                Los siguientes cuatro estudios se denominaron SCA-\n   tamine-regulated transcript) e indirectamente inhibien-                       LE (Satiety and Clinical Adiposity — Liraglutide Eviden-\n   do los neurotransmisores en neuronas que expresan                             ce) y se realizaron en distintas situaciones con obesidad\n   neuropéptido-Y y de AGRP (agouti-related peptide), vía                        para conocer la eficacia y seguridad del fármaco en\n   GABA (ácido gamma-aminobutírico), en el núcleo ar-                            diferentes grupos de pacientes. En la figura 1 se resu-\n   cuato del hipotálamo. Al mismo tiempo, produce un                             men todos los ensayos clínicos realizados con liragluti-\n   enlentecimiento moderado del vaciamiento gástrico                             da 3,0 mg. En el estudio SCALE obesidad y prediabetes\n   que contribuye a implementar la sensación de plenitud                         se incluyeron 3731 pacientes (39% con obesidad sin\n   y saciedad tras la ingesta. Este efecto supone una pér-                       prediabetes y 61% con obesidad y prediabetes) se ob-\n   dida entre 2-3 kg de promedio en las personas con                             jetivó que la pérdida de peso de ambos grupos al cabo\n   diabetes que son tratadas con liraglutida a las dosis\n   mencionadas24. Pero precisamente fue este efecto inhi-                        de 56 semanas fue del 8% (2,6% con placebo). Ade-\n                                                                                 más, liraglutida 3 mg redujo en 8 veces la posibilidad\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}